2334 GMT - Wider adoption of Pro Medicus's medical-imaging tech looks inevitable to its bulls at Goldman Sachs. Calling Pro Medicus one of Australia's best global growth companies, GS analysts write in a note that they expect a strong increase in the cadence and value of contract wins over time. Adoption is a matter of when, not if, they reckon. The analysts think that there is potential for material upside from outsized contracts worth more than A$100 million, but they acknowledge that visibility here is limited in terms of both size and timing. GS lifts its target price 26% to A$278.00 and keeps a buy rating on the stock. Shares are up 3.7% at A$256.29. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 11, 2024 18:34 ET (23:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。